The role of SIRT1 in diabetic cardiomyopathy - 04/05/17
pages | 7 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Abstract |
The prevalence of diabetes mellitus (DM) has been increasing worldwide. Diabetic cardiomyopathy (DCP) is the major risk for diabetes associated morbidity and mortality. Hyperglycemia and hyperinsulinemia play an indispensable role in underlying mechanisms of DCP. They increase advanced glycation end products (AGEs) following a series of events leading to myocardial damage and cardiomyopathy which include oxidative stress, increased inflammation, fibrosis, hypertrophy and apoptosis. SIRT1 is a nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase that removes acetyl groups from proteins which can be implicated in DCP. SIRT1 modulate different proteins related to hyperglycemia. SIRT1 inhibits transcriptional factors, such as p300, NF-κB, P38MAPK, Histone 3, MMP-9, FOXO3a and p53. On the other hand, it increases SERCA2a, ERK1/2/Homer1, eNOS, PGC-1α and AMPK. Therefore, SIRT1 attenuate cardiac dysfunction and improve DCP. This review focus on the role of SIRT1 in diabetic cardiomyopathy.
Le texte complet de cet article est disponible en PDF.Abbreviations : SIR2, HDACs, NAD +, DM, CAD, HF, DCP, MRI, MAPK, JNK, ERK, AGEs, AMPK, UPR, ER, SERKA2a, LVH, TGFB1, NF-κB, MMP-9, CHM, IGF-1, PARP1, NO, I/R, FOXO, PI3K, PGC-1α
Keywords : Cardiomyopathy, Diabetes, Oxidative stress, SIRT1
Plan
Vol 90
P. 386-392 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?